News | Heart Failure | March 08, 2017

Ohio State First in U.S. to Test New Congestive Heart Failure Treatment

Catheter-based treatment targets the lymphatic system to drain excess fluid buildup caused by heart failure

March 8, 2017 — A Whitehall, Ohio man is the first in the United States to undergo a brand new treatment designed to remove excess fluid from hospitalized patients suffering from congestive heart failure, which affects six million Americans. The trial procedure occurred recently at The Ohio State University Richard M. Ross Heart Hospital.

Ohio State cardiovascular researchers are testing the safety and feasibility of inserting a special catheter to improve the flow of fluid from the lymphatic system. Lymphatic vessels help remove fluid from tissues and return it to the body’s circulatory system. Excess fluid is then eliminated by the kidneys. The lymphatic system typically drains up to two gallons of fluid per day. In acute congestive heart failure, this process is impeded, allowing fluid build-up, or edema, to occur in the lungs and other areas of the body. Edema is a major symptom in heart failure, and this novel therapy aims to treat one of the underlying causes.

Ohio State is first to conduct the procedure and is one of only two test sites in the U.S., along with Advocate Christ Hospital in Chicago.

“Most of the recent advancements in heart failure have been for non-hospitalized patients, to help keep them well,” said Sitaramesh Emani, M.D., a cardiologist and director of heart failure clinical research at Ohio State, who performed the procedure. “We need new therapies for patients once they’ve become hospitalized. There hasn’t been a lot of new development there.”

Raynes Rozzelle, 61, has lived with various heart issues most of his life – from a heart murmur, to an irregular heartbeat, and then a heart attack four years ago. He’s been in and out of the hospital with congestive heart failure for about a year. He says he readily agreed to try something new.

“I thought, not only could this possibly help me, it may end up helping a lot of other people. I was raised to help others whenever you can,” Rozzelle said.

The treatment, developed by WhiteSwell Medical, is the first known catheter specifically designed to target the lymphatic system internally. The device is placed in the neck under ultrasound guidance in the catheterization lab, and the treatment continues at the bedside using a machine that helps circulate some of the blood.

Currently, in-hospital treatment for congestive heart failure involves removing excess fluid with diuretic medication and/or ultrafiltration, in which a machine bypasses the kidneys and filters water and salt from the body. However, the treatments can have unwanted side effects such as low blood pressure and worsening kidney function.

“In some cases, the diuretics provide only partial relief, so there’s a need for new options for treating the congestion associated with heart failure,” said Garrie Haas, M.D., lead investigator on the study and director of the Ohio State advanced heart failure program. “More efficient and effective treatment not only improves the patient’s quality of life, it can reduce re-hospitalizations, so we’re interested in trying this new approach.”

According to the Centers for Disease Control, heart failure is the most common reason for hospital admission in those ages 65 and older, and it accounts for one million admissions each year in the U.S.

Read the article “Device Technologies to Reduce Heart Failure Readmissions.”

For more information: www.wexnermedical.osu.edu

Related Content

First-in-Man RenalGuard Studies Show Promise for Heart Failure Patients
News | Heart Failure| January 02, 2018
RenalGuard Solutions Inc. reported positive results from a first-in-man feasibility study focusing on a novel use of...
ACC Issues New Guidance to Optimize Heart Failure Treatment
News | Heart Failure| December 22, 2017
December 22, 2017 — To help streamline treatment of patients with...
Coffee Associated With Reduced Risk of Heart Failure, Stroke. AHA 2017. #AHA2017
News | Heart Failure| November 25, 2017
November 25, 2017 — Drinking coffee may be associated with a decreased risk of developing heart failure or having str
Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years among U.S. veterans, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.
News | Heart Failure| November 25, 2017
November 25, 2017 — Heart failure associated with methamphetamine (meth) use has risen dramatically in recent years a
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure| November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
News | Heart Failure| November 13, 2017
November 10, 2017 — Moderna Therapeutics announced a new license and collaboration with AstraZeneca to co-develop and
Scientists Reverse Advanced Heart Failure in Mouse Model
News | Heart Failure| October 30, 2017
October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart.
Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
Overlay Init